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Abstract 
Background 
Left ventricular global longitudinal systolic strain (GLS) has been shown to be superior to ejection fraction (EF) in 
detecting subclinical dysfunction in cancer patients and predicting mortality in patients with cardiovascular disease. 
Cancer-related fatigue is common in the later stages of neoplastic malignancies and may be indicative of non-overt heart 
failure. In this study we sought to determine whether reduced strain by echocardiography was associated with all-cause 
mortality in a cancer cohort. 
Methods 
In this retrospective study, one hundred and twenty patients with cancer undergoing or scheduled to undergo 
chemotherapy and with a normal EF (> 50%) had assessments of GLS. GLS was derived by averaging all speckle tracking 
strain segments of the left ventricle. 
Results 
Over an average follow-up of 21.6 ± 13.9 months, 57/120 patients died. Univariate predictors of all-cause mortality 
(p<0.10) were Eastern Cooperative Oncology Group Performance Status (ECOGPS), male sex, hematologic malignancy, 
beta blocker usage, and GLS. Multivariate analysis of all significant univariate variables showed that ECOGPS (p<0.001, 
HR 2.12 [1.54-2.92]), male sex (p=0.014, HR 1.93 [1.14-3.27]), and GLS (p=0.012, HR 0.89 [0.81-0.97]) were significant ly 
and independently associated with mortality. Stepwise analysis of the multivariate associations showed an increase in 
global χ2 after adding GLS (p=0.011) to significant clinical variables.  
Conclusions 
ECOGPS, male sex, and GLS were significantly associated with all-cause mortality in cancer patients with normal EFs 
receiving chemotherapy. Adding GLS to significant clinical variables provided incremental prognostic information. 
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Introduction 
Left ventricular ejection fraction (EF) has long been considered the standard for assessing cardiac function in most 
cardiac disorders and in monitoring chemotherapy-induced cardiotoxicity. However, EF rarely declines to a measurable 
degree from some chemotherapy agents (i.e. anthracyclines) until irreversible and symptomatic damage has been 
done.[1] Strain echocardiography (SE) is an emerging technique that has been shown to be clinically useful due to its 
ability to detect myocardial dysfunction earlier and with greater sensitivity than EF or wall motion analysis. Left 
ventricular global longitudinal systolic strain (GLS) has been demonstrated to be a significant predictor of chemotherapy-
induced cardiotoxicity in patients with preserved EF.[2]  It has also been demonstrated to be a predictor of multiple 
outcomes including all-cause mortality in patient populations with a strong prevalence of cardiac disease.[3-7] This 
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suggests that reduced strain is associated with death from cardiac disease. However, SE has not been investigated for its 
potential to predict death independently of underlying cardiac disease. 
Since cancer-related fatigue (CRF) worsens as cancer progresses, it stands to reason that some factors responsible for 
CRF may correlate with mortality in cancer patients.[8] Schünemann et al noted that CRF may be associated with 
subclinical cardiac dysfunction.[9] Thus, we investigated whether mortality in cancer patients without excess cardiac 
disease was associated with reduced cardiac function on SE. 
We compared the association of strain by SE with mortality against clinical performance status which is a validated 
measure of determining prognosis across multiple cancer types.[10-13]    
Methods 
Study Population 
This study was approved by the Indiana University Institutional Review Board. We queried the echocardiography 
database (Fuji Synapse 4.0 Indianapolis, IN) for patients with cancer who had echocardiograms with strain 
measurements performed in relation to chemotherapy or bone-marrow transplants. Per laboratory policy, if possible 
strain was calculated at the time of echocardiogram for all studies ordered either as standard cardiac monitoring for 
chemotherapy regiments and in symptomatic patients with concern of chemotherapy-related cardiac toxicity. We 
identified 138 patients from 2009-2011 cared for at the Indiana University Simon Cancer Center who had both 2D echo 
images and pre-existing speckle tracking polar plots calculated directly on the instrument consoles. We excluded 
patients with known systolic dysfunction (14 patients with LVEF < 50% and one patient on inotropic therapy) and 
patients with overall poorly tracking strain studies (n=3). The study population was thus comprised of 120 
retrospectively identified patients with a history of recent or imminent chemotherapy, a normal EF, and previously 
acquired strain images. Nine patients obtained their study before ever receiving chemotherapy for their active 
malignancy. 
Clinical Data Methods 
The clinical history was obtained via chart review in which the type of malignancy, age at time of last visit/death, sex, 
beta blocker usage, ECOGPS, and various comorbidities were documented from approximately the time the echo was 
performed. Any past or imminent exposures to anthracyclines were recorded. Eastern Cooperative Oncology Group 
Performance Status (ECOGPS) and Karnofsky Performance Status (KPS) are widely validated tools for measuring 
performance status and are often used to predict mortality for multiple cancer types.[11] ECOGPS was taken from 
oncology clinic/consult notes. See Table 1 for clinical descriptions of the different ECOGPS grades.  
For cases in which only KPS was available, the value was converted to an ECOGPS grade as in equation 1. Four patients 
without distinct documentation of performance status had notes that heavily implied no functional limitations and were 
counted as an ECOGPS of 0.  
Equation 1. 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅(5 − 𝐾𝐾𝐾𝐾𝐾𝐾
20
) = 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 
To determine if cancer was a likely cause of death, all patients that died were analyzed via chart review for the presence 
of advanced (i.e. potentially rapidly fatal) cancer and for any clinical indications of subsequent cardiotoxicity defined as 
an absolute drop in EF>10% to a level below 50% at the time of the last echo not readily explained by another acute 
process. 
Echocardiographic Acquisition 
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Two-dimensional echocardiographic measurements were performed using a Vivid 7 or Vivid Q echograph (General 
Electric Medical Systems, Milwaukee, WI). The echocardiographic examinations were performed according to ASE 
guidelines.[14] The images were recorded digitally and analyzed off line (Fuji Synapse 4.0 Indianapolis, IN).  
Strain Acquisition 
The strain measurements were obtained by experienced sonographers using a Vivid 7 and Vivid Q echograph (General 
Electric Medical Systems, Milwaukee, WI) at the same time that the standard 2D echocardiograms were performed. To 
make the speckle tracking strain calculations, apical 4, 3, and 2-chamber views were stored in a cine loop format. Images 
were obtained between 50-70 frames per second. The analysis was made at the conclusion of the examinations using a 
propriety software package on the instrument. The software used requires the operator to identify three points on each 
view (the two mitral annulus attachments to the myocardium and also the apex). The software then automatically 
determines the strain measurements in the six segments of each view. The calculated peak strain values for the entire 
myocardium can then be displayed as a 17 or 18 segment polar plot, or “bull’s eye” diagram. The software calculates an 
average strain value for each view individually then a global average incorporating all three (Figure 1).  
GLS measurements were taken directly from the polar plot screen without adjustment. Those echocardiograms in which 
a polar plot could not be constructed were not considered. A high threshold was maintained for excluding any remaining 
strain echocardiograms based on strain calculations which appeared grossly inaccurate, and only one strain 
echocardiogram was excluded by this criterion. In this case 8 of 18 contiguous segments were calculated as either 
expanding during systole or non-tracking yet without any echocardiographic or clinical findings to substantiate a regional 
dysfunction. 
Reproducibility  
As our institution does not have the capability to retrospectively collect strain reproducibility data using the native GE 
software, we used data we had prospectively collected from a general cohort of patients that had echocardiograms 
ordered and performed at roughly the same time as the study patients. Inter-observer and intra-observer variability 
were measured using different cohorts of patients (n=36 for both) with various pathologies and with EF>50%. These 
studies had repeat strain analyses performed by the same sonographer or by a different sonographer for the purposes 
of determining reproducibility. 
Outcomes 
All-cause mortality was the primary end point. Follow-up was obtained by using the patient’s hospital and clinic charts, 
online obituary records, or the Social Security Death Index. 
Statistical Analysis 
Analysis was carried out using SPSS (version 16, SPSS Inc., Chicago, Ill). To simplify analysis and communication, all strain 
values were multiplied by -1 such that greater positive strain values refer to greater myocardial contraction and vice-
versa.[15] The χ2 test was used to determine significant differences between 2 groups of categorical or continuous 
variables. 
Univariate binary logistic regression was performed to determine if variables which might affect strain such as age, sex, 
time from chemotherapy to echo, prior thoracic radiation, prior anthracycline use, hypertension, coronary artery 
disease, or diabetes mellitus were independently associated with an abnormal GLS defined as <18.  
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Survival was assessed using Kaplan-Meier analysis and significant differences in survival were assessed with log-rank 
test. Cox proportional hazards analysis was used to determine significant univariate factors associated with all-cause 
mortality. Two different types of multivariate analyses were performed. The initial analysis was conducted with a 
forward selection method including all clinical and echocardiographic variables with p < 0.10 on univariate analysis. 
Variables with p < 0.05 on multivariate analysis were considered significantly and independently associated with 
mortality. A second stepwise analysis was performed using the clinical variables that were independently associated 
with mortality in the first step and SE variables in the second step to determine if strain variables added incremental 
prognostic value. Reproducibility was reported as the average percent measurement difference/mean. 
Results 
Table 2 contains the clinical and echocardiographic information for the population. Table 3 provides a breakdown of the 
malignancies. There are 122 malignancies as two patients had two simultaneous primary cancers. Only 4 patients (3%) 
had significant coronary disease. One of the surviving patients had minimal records available after leaving the country 
and thus was the only survivor with <14 months of follow-up.  Aside from one patient with mild-to-moderate valvular 
disease, all patients had no more than mild valvular disease.  
Over 21.6 ± 13.9 months of follow-up, there were 57/120 deaths (48%). One patient died from heart failure thought to 
be due primarily to chemotherapy induced cardiotoxicity, and one patient died abruptly without signs of cardiotoxicity 
or an active malignancy at last follow-up. The remaining 55 patients had advanced cancer at last follow-up prior to 
death.  
Binary logistic regression  showed that among the risk factors of age, sex, time from chemotherapy to echo, prior 
thoracic radiation, prior anthracycline use, hypertension, coronary artery disease, and diabetes mellitus, only HTN 
(p=0.064) and CAD (p=0.009) had p value significance <0.10 associated with a decreased GLS.  
Table 4 shows the results of univariate and multivariate analyses of all clinical and echocardiographic variables. In this 
set of variables the significant univariate factors associated with mortality (p <0.1) were male sex, ECOGPS, hematologic 
malignancy, beta blocker usage, and GLS. Neither prior anthracycline use nor prior thoracic radiation was associated 
with mortality. On multivariate analysis of the significant univariate associated factors, male sex, ECOGPS, and GLS were 
independently associated with mortality.  
A second multivariate analysis was done starting with the significant independent clinical variables (male sex and 
ECOGPS). GLS was added via stepwise block analysis to these clinical parameters and was found to be significant 
(p=0.011) as detailed in Figure 2. 
Figure 3 demonstrates the Kaplan-Meier survival curve comparing abnormal GLS (<18) to normal GLS (≥18). Of note 48% 
of the patients with abnormal GLS (25/52) died within 12 months of the strain echo compared with only 24% of the 
group with normal GLS (16/68).  
The interobserver and intraobserver reproducibility for our facility is 7.3% and 5.8% for GLS respectively and 7.7% and 
8.7% for EF respectively.  
Discussion 
The present study demonstrates that GLS is independently associated with mortality in cancer patients with preserved 
EF and adds incremental prognostic value when added to clinical variables.  
Strain as a nonspecific marker of prognosis in cancer patients  
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While the specific causes of death for the study population are unknown, it is reasonable to assume that an 
overwhelming majority of patients died primarily from their malignancies as opposed to cardiotoxicity as all but two 
were noted to have advanced symptomatic cancer at the time of their last contact with our facility prior to death. Limat 
et al found that among 147 lymphoma patients treated with aggressive cardiotoxic therapy only 3 died from early 
cardiotoxicity (within 1 year).[16] Given that our sample population did not have a significantly elevated rate of known 
hypertension or cardiac disease, a normal initial EF, and a normal mean wall thickness, it is reasonable to think that 
cardiac disease would be a lesser contributor to the high mortality in this group. Also, given that this cohort was exposed 
to a wide range of treatment modalities, it is not surprising that only one patient had definitive cardiac death from 
cardiotoxicity. Our data thus implies strain detects changes in cardiac function caused by certain forms of severe illness. 
The pathophysiology for this process is unknown. Although at least a portion of this phenomenon is believed to be a 
direct result of chemotherapy, the lack of significance of anthracycline exposure as a univariate factor associated with 
mortality and the lack of association with reduced GLS argues against this. One possible explanation is the increased 
amount of inflammatory cytokines. Severe cancer has been known to cause systemic “B-type symptoms” such as fever, 
chills, fatigue, and cachexia. CRF and cachexia are both associated with elevated inflammatory cytokines.[17-20] In 
addition, cachexia has been noted to cause myocardial dysfunction in animal models.[21] High levels of inflammatory 
cytokines are associated with a poor prognosis in cancer patients and with worsening cardiac disease including systolic 
dysfunction in more general cohorts.[22, 23] Thus, patients with a poor prognosis may have worse GLS due to increased 
inflammatory cytokines. It is currently unknown which cytokines may be most influential, but TNFα, CRP, and IL-6 are 
frequently documented in both cardiac dysfunction and cachexia.[19, 20, 22] In other words, perhaps SE detects cancer-
induced cardiac stress, a phenomenon that should worsen as cancer progresses. In the event this process is accurate, 
GLS would be an indicator of disease burden in cancer patients.  
Another possible mechanism by which decreased strain may be associated with mortality in this population is due to 
increased autonomic dysfunction. Many studies have been published showing the high incidence of autonomic 
dysfunction in cancer patients.[8, 24, 25] The most frequently discussed are cardiovascular consequences of this process 
such as orthostatic hypotension and loss of heart rate variability The severity of autonomic dysfunction has been 
correlated with time to death in cancer patients in several studies. Given that autonomic dysfunction can cause 
myocardial dysfunction, perhaps this too is a mechanism by which decreased strain correlates with mortality.[26] This is 
likely through a phenomenon of overriding adrenergic activity which is also a well-known component of heart 
failure.[27, 28] Increased adrenergic activity is common in cancer patients and is even suggested to be a cause of weight 
loss in these patients.[29] Cramer et al recently demonstrated how cardiovascular function was impaired in colorectal 
cancer patients regardless of whether or not they were receiving chemotherapy.[30] In their analysis they also noted 
how the heart rate variability was reduced and similar to that seen in patients with CHF.  
Strain has been shown to be an excellent predictor of cardiac death in patients with pre-existing cardiac disease, but it 
has not been studied for its potential to predict non-cardiac death. Given the maladaptive systemic processes associated 
with end-stage cancer during the last few months of life, it can be difficult to call any non-traumatic death in these 
patients as unrelated to the existing malignancy regardless of the organ or organs whose failure are the ultimate cause 
of death. A potential exception to this would be organ failure and death as a result of drug toxicity. Agents such as 
trastuzumab, sunitinib, and doxorubicin all can cause cardiac dysfunction and clinical heart failure through direct or 
indirect means, but it is highly unlikely for such an agent to cause fatal heart failure over a rapid course during our 
monitoring period and go unrecognized. Another possible method of cardiac death in this population is sudden cardiac 
death as a result of a drug-induced arrhythmia. Typically sudden cardiac death is defined as a rapid and unexpected 
death from cardiac causes with or without known underlying heart disease.[31] In patients with advanced cancer and a 
poor life expectancy, sudden cardiac death is arguably impossible since the death is never unexpected. Myocardial 
infarction is another potential cause of rapid death in this population and is typically associated with agents such as 5-FU 
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and Cisplatin, but it also has very low incidence and typically occurs shortly after drug administration and would thus not 
likely go unrecognized. Thus, it is a fairly safe assumption that nearly all of the deaths in our study population were 
noncardiac in nature. Aside from the one known patient that died from cardiotoxicity, there was only one other patient 
who died that did not appear to be approaching end-stage cancer at the time of his last visit. While having an exact 
cause of death for this patient may be preferable, it would have little impact on this study. 
On univariate analysis beta-blocker use appeared to be associated with mortality but it was not independently 
associated with mortality on multivariate analysis. Beta-blockers are frequently used to treat cardiotoxicity, so their use 
in this population being associated with mortality is curious. Most likely, with a p= 0.046 this could be entirely due to 
chance particularly in light of the number of variables analyzed. With such a low prevalence of usage and questionable 
significance it is difficult to draw firm conclusions. 
Limitations 
The present study deserves several comments. Cancer subtypes are not homogenous in their pathology and their 
systemic effects vary between subtypes. As such, it is not ideal to group different types of cancer together for analysis. 
Our database only had access to 120 eligible patients with both cancer and strain measurements and thus further group 
delineations by cancer type, specific chemotherapy agents and cumulative dosage,  and the timing of the echo on the 
outcome were not possible to produce significantly powerful statistics. This study was not designed to have an impact 
on the management of oncology patients, but to test the hypothesis that some noncardiac diseases may influence strain 
proportionally to their severity.  
 This is a retrospective study performed at a tertiary referral center. There is no offline strain calculation software at our 
institution so all strain analyses had to be done by the sonographers on the instruments at the time of the echo before 
moving the study to offline storage. There is likely some degree of selection bias since not every patient at our 
institution with cancer had an echo study with strain. This is particularly true for those that were treatment-naïve. Also, 
our sonographers are encouraged to abort any efforts in acquiring strain if they notice the tracking quality to be poor. In 
most other cancer patients, a MUGA scan or an echo without strain may be obtained instead of a strain echo due to 
preference, convenience, level of experience, or the availability of strain-capable instruments. The oncologists are 
responsible for ordering exams for their patients and they have different criteria for ordering an echo over another 
imaging modality when they feel it is indicated. Of note, all of these exams were performed before the recent 
cardiotoxicity monitoring consensus statement was published. [33] 
In spite of the limitations of the study the results suggest that a single SE performed at some point in the course of 
cancer treatment provides incremental prognostic information when combined with patient sex and performance 
status.  
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Figure 1. Sample strain polar plots for (A) a patient with abnormally low GLS (15.8, normal ≥ 18) who died within 12 
months of this study and for (B) a patient with normal GLS (20.8) who did not die within the follow-up period of over 26 
months. High strain values (most negative) are colored deep red. Lower values (less negative) are lighter red and 
reversed strain values (positive, not pictured) are shades of blue. Note that the strain values have been multiplied by (-1) 
in the article text to simplify descriptive language. GLPS_Avg = left ventricular global longitudinal systolic strain. 
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Figure 2. Stepwise addition of GLS to the clinical independent mortality 
variables.  On multivariate stepwise block analysis, adding GLS to the 
clinical independent mortality variables (ECOGPS and sex) gives significant 
additional prognostic value. GLS = left ventricular global longitudinal 
systolic strain. 
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Figure 3. Kaplan-Meier curves for normal and abnormal GLS.  
Separating all patients into normal (≥18) and abnormal (<18) GLS gives two groups with significant differences in 
mortality, particularly at 6-12 months. Remaining patients in each group are listed at 0, 12, 24, 36, and 48 months. GLS = 
left ventricular global longitudinal systolic strain 
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Table 1. ECOGPS grades[11] 
ECOGPS Grade* Description 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about 
more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
5 Dead 
*Reproduced courtesy of Robert Comis M.D., Group Chair, Eastern Cooperative Oncology Group; ECOGPS = Eastern 
Cooperative Oncology Group Performance Status 
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Table 2. Clinical and echocardiographic variables 
Clinical/Echo Variables Avg or prevalence (n=120) 
Age (yrs) 53.1 ± 12.4 
Months from echo to follow-up/death 21.6 ± 14.0 
Months from chemo to echo 29.3 ± 39.3 
Male sex 43 (36%) 
ECOGPS 0.48 ± 0.72 
Hematologic malignancy  52 (43%) 
History of anthracycline use  69 (58%) 
History of thoracic radiation 31 (26%) 
Beta blocker usage  24 (20%) 
ACE-I usage 26 (22%) 
Statin usage 20 (17%) 
Salicylate usage 15 (13%) 
Diabetes mellitus 18 (15%) 
Coronary artery disease 4 (3%) 
Hypertension 42 (35%) 
Tobacco use 37 (37%) 
Hyperlipidemia 29 (24%) 
Ejection fraction  61.1 ± 5.0 
LVEDV (mL) 127.3 ± 41.9 
IVS diastolic thickness (cm) 1.04 ± 0.15 
LVPW diastolic thickness (cm) 1.03 ± 0.12 
Left atrial volume index (mL/m2) 17.8 ± 6.7 
Mitral E/e’** 9.39 ± 2.76 
Values are mean ± SD or n (%) 
**Mitral E/e’ data interpretable in 59 survivors and 49 non-survivors 
ECOGPS = Eastern Cooperative Oncology Group Performance Status; IVS = intraventricular septum; 
LVPW = left ventricle posterior wall; LVEDV = left ventricle end diastolic volume  
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Table 3. Breakdown of patient malignancies 
Cancer Type Died (%) 
ALL 5/8 (63) 
AML 14/19 (74) 
CLL 1/2 (50) 
CML 0/1 (0) 
Hodgkin's lymphoma 0/5 (0) 
Non-Hodgkin's lymphoma 8/12 (67) 
Myeloma† 2/6 (33) 
Breast Cancer 8/42 (19) 
Carcinoid Cancer 3/3 (100) 
Colorectal Cancer 2/4 (50) 
Endometrial Cancer 0/1 (0) 
Esophageal Cancer 2/2 (100) 
Head and Neck Cancers 3/3 (100) 
Lung Cancer 2/2 (100) 
Ovarian Cancer 1/3 (33) 
Pancreatic Cancer 3/3 (100) 
Renal Cancer 5/6 (83) 
All Cancer 59/122 (48) 
†Includes multiple myeloma and plasmacytoma; ALL = acute lymphocytic leukemia; AML = acute myelogenous leukemia; 
CLL = chronic lymphocytic leukemia; CML = chronic myelogenous leukemia  
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Table 4. Cox analysis of clinical and echo variables 
 Univariate Multivariate‡§ 
Variables Survived (n=63) Died (n=57) HR 95% CI p HR 95% CI p  
Age 52.1 ± 11.9 54.3 ± 12.9 1.01 0.99-1.04 0.255    
Time (echo to end) 31.9 ± 8.6 10.2 ± 8.9 ----- ------------ ----------    
Time (chemo to echo) 32.0 ± 41.7 26.4 ± 36.3 1.00 0.99-1.00 0.416    
Male sex 14 (22) 29 (51) 2.26 1.34-3.81 0.002 1.93 1.14-3.27 0.014 
ECOGPS 0.2 ± 0.5 0.8 ± 0.9 2.16 1.63-2.87 <0.001 2.12 1.54-2.92 <0.001 
Hematologic malignancy 23 (37) 29 (51) 1.69 1.00-2.84 0.051   0.693 
Hx of anthracycline use 36 (57) 33 (58) 1.13 0.67-1.13 0.652    
Hx of thoracic radiation 18 (29) 13 (21) 0.77 0.41-1.43 0.408    
Beta blocker usage  9 (14) 15 (26) 1.83 1.01-3.31 0.046   0.130 
ACE-I usage 15 (24) 11 (19) 0.78 0.41-1.51 0.465    
Statin usage 9 (14) 11 (19) 1.31 0.68-2.54 0.417    
Salicylate usage 9 (14) 6 (11) 0.76 0.32-1.76 0.515    
Diabetes mellitus 9 (14) 9 (16) 1.24 0.61-2.53 0.552    
Coronary artery disease 1 (2) 3 (5) 2.24 0.69-7.20 0.178    
Hypertension 20 (32) 22 (39) 1.31 0.77-2.23 0.323    
Tobacco use 17 (27) 20 (34) 1.36 0.79-2.34 0.273    
Hyperlipidemia 12 (19) 17 (30) 1.41 0.80-2.48 0.239    
Ejection fraction  61.3 ± 4.6 60.8 ± 5.5 0.99 0.93-1.04 0.602    
LVEDV  129.7 ± 41.0 124.5 ± 43.1 1.00 0.99-1.00 0.378    
IVS diastolic thickness  1.04 ± 0.15 1.05 ± 0.14 2.05 0.37-11.48 0.412    
LVPW diastolic thickness  1.01 ± 0.11 1.04 ± 0.14 3.87 0.46-32.55 0.213    
Left atrial volume index  17.45 ± 6.02 18.17 ± 7.61 1.01 0.97-1.06 0.645    
Mitral E/e’# 9.34 ± 2.58 9.45 ± 2.96 1.02 0.92-1.15 0.668    
GLS 19.12 ± 2.37 17.72 ± 3.10 0.85 0.77-0.94 0.001 0.89 0.81-0.97 0.012 
Values are mean ± SD or n (%) when appropriate 
‡using univariate predictors with p<0.10 as candidate variables  
§Multivariate significance defined as p<0.05 
#Mitral E/e’ data interpretable in 59 survivors and 49 non-survivors 
HR = hazard ratio; CI = confidence interval; ECOGPS = Eastern Cooperative Oncology Group Performance Status; ACE-I = 
angiotensin converting enzyme inhibitor; IVS = intraventricular septum; LVPW = left ventricle posterior wall; LVEDV = left 
ventricle end diastolic volume; GLS = left ventricular global longitudinal systolic strain;  
 
